Description
This video transcript details a launch event for Arthrosamid, a new product by Contura designed for the treatment of osteoarthritis. Sean Curry hosts the event, introducing Professor Henning Bliddal, a rheumatology expert engaged in clinical research, who shares insights about the increasing prevalence of osteoarthritis, particularly in younger populations due to factors like obesity and longer lifespans. He emphasizes a comprehensive approach to treatment that includes physical, chemical, and surgical interventions, stressing that surgery should be a last resort.
The discussion covers various treatment options ranging from lifestyle changes to medications, highlighting the pros and cons of current therapies like glucosamine supplements, injections, and other drugs which typically have side effects. The audience is prepared for insights from both Dr. Ieva Ankorina-Stark, the Chief Scientific Officer of Contura, who will delve into the scientific foundations of Arthrosamid, and further clinical data from Professor Bliddal regarding its efficacy and safety, which has been supported by extensive preclinical testing.
Dr. Ankorina-Stark narrates the journey of Arthrosamid, explaining its biocompatibility and development through rigorous testing over two decades, noting its recent approval for market release in Europe and the UK. The hydrogel is presented as a promising solution for those battling osteoarthritis, with many preliminary animal studies indicating its potential to integrate well into the joint areas without causing inflammatory reactions.
Professor Bliddal then presents clinical study results, showcasing significant improvements in patients' pain levels measured by WOMAC scores after receiving injections of Arthrosamid, without the significant adverse effects commonly associated with conventional treatments. The session concludes with a strong endorsement of Arthrosamid as a safe, effective alternative treatment, urging further investigation through randomized controlled trials.